Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Segment Information - Additional Information (Details)

v3.24.0.1
Segment Information - Additional Information (Details)
€ in Thousands
 12 Months Ended
Dec. 31, 2023
EUR (€)
Dec. 31, 2022
EUR (€)
Customer
Dec. 31, 2021
EUR (€)
Customer
Disclosure of operating segments [line items]      
Number of external customers exceeded 10% group's revenue | Customer   0 0
Revenue € 1,085,354 € 983,680 € 843,920
External Customers      
Disclosure of operating segments [line items]      
Revenue 1,085,354 983,680 843,920
Biopharmaceutical and Diagnostic Solutions | Operating Segments      
Disclosure of operating segments [line items]      
Revenue 881,337 801,237 695,172
Biopharmaceutical and Diagnostic Solutions | Operating Segments | External Customers      
Disclosure of operating segments [line items]      
Revenue 879,288 799,652 694,038
Engineering | Operating Segments      
Disclosure of operating segments [line items]      
Revenue 372,807 299,500 218,861
Engineering | Operating Segments | External Customers      
Disclosure of operating segments [line items]      
Revenue 206,066 184,028 149,882
Total Segments | Operating Segments      
Disclosure of operating segments [line items]      
Revenue 1,254,144 1,100,737 914,033
Total Segments | Operating Segments | External Customers      
Disclosure of operating segments [line items]      
Revenue € 1,085,354 € 983,680 € 843,920
Total Segments | Operating Segments | Customer      
Disclosure of operating segments [line items]      
Percentage of revenue 11.40%    
Revenue € 123,600